These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19642236)

  • 1. GlaxoSmithKline, Pfizer to merge HIV drug units in new company.
    AIDS Read; 2009; 19(6):206. PubMed ID: 19642236
    [No Abstract]   [Full Text] [Related]  

  • 2. Sugen falls as casualty of Pfizer-Pharmacia merger.
    Garber K
    Nat Biotechnol; 2003 Jul; 21(7):722-3. PubMed ID: 12833079
    [No Abstract]   [Full Text] [Related]  

  • 3. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 4. Roche and Igen in shotgun wedding.
    Bouchie A
    Nat Biotechnol; 2003 Sep; 21(9):958. PubMed ID: 12949542
    [No Abstract]   [Full Text] [Related]  

  • 5. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceutical companies join forces on HIV.
    Butler D
    Nature; 2009 Apr; 458(7241):950-1. PubMed ID: 19396104
    [No Abstract]   [Full Text] [Related]  

  • 7. GlaxoSmithKline, under pressure, cuts price of AIDS treatment for poor countries.
    Fleck F
    Bull World Health Organ; 2003; 81(6):469. PubMed ID: 12894339
    [No Abstract]   [Full Text] [Related]  

  • 8. The looming crisis in drug pricing.
    Delaney M
    GMHC Treat Issues; 2002 Apr; 16(4):12. PubMed ID: 12141258
    [No Abstract]   [Full Text] [Related]  

  • 9. Africa finds drug giants guilty of excessive pricing.
    AIDS Policy Law; 2003 Dec; 18(22):5. PubMed ID: 14974397
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiinfective biotechs face partnering gap.
    Sheridan C
    Nat Biotechnol; 2005 Feb; 23(2):155-6. PubMed ID: 15696131
    [No Abstract]   [Full Text] [Related]  

  • 11. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 12. Essential AIDS medications in India.
    Thomas J
    Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
    [No Abstract]   [Full Text] [Related]  

  • 13. Exiting this year and into the next.
    Nat Biotechnol; 2005 Dec; 23(12):1451. PubMed ID: 16333272
    [No Abstract]   [Full Text] [Related]  

  • 14. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
    James JS
    AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genentech makes its first-ever acquisition.
    Hollmer M
    Nat Biotechnol; 2007 Jan; 25(1):4-5. PubMed ID: 17211375
    [No Abstract]   [Full Text] [Related]  

  • 16. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

  • 17. The changing outlook for worldwide HIV treatment.
    Gonsalves G
    GMHC Treat Issues; 2001 Apr; 15(4):3-5. PubMed ID: 11590941
    [No Abstract]   [Full Text] [Related]  

  • 18. [Glaxo Wellcome, Germany, spends 60.000 DM for African HIV projects in Uganda and Malawi].
    Krankenpfl J; 1999 Dec; 37(12):479. PubMed ID: 10734858
    [No Abstract]   [Full Text] [Related]  

  • 19. Glaxo drops drug prices, AIDS foundation drops suit.
    AIDS Policy Law; 2003 May; 18(10):6. PubMed ID: 12809097
    [No Abstract]   [Full Text] [Related]  

  • 20. Activists dialog about pricing.
    AIDS Patient Care STDS; 1999 Apr; 13(4):247. PubMed ID: 10351896
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.